Maybe the Seattle biotech company should respond by offering Brad Loncar a seat on its board.
FORBES: Dendreon's Scientific Breakthrough Fails To Sell
2.
Neither you nor I nor Brad Loncar nor Mitchell Gold has a good answer.
FORBES: Dendreon's Scientific Breakthrough Fails To Sell
3.
Brad Loncar, a former Dendreon investor (he still owns one share) who has been pushing for Dendreon to change its management, he declared victory in an email this morning.
FORBES: Why CEO Replacement Is Good News For Dendreon